Bioventus (US:BVS)2025-12-03 15:10Financial Performance & Growth - The company reported Last Twelve Months (LTM) global proforma revenue of $564 million[7] - The company is experiencing above-market revenue growth, with eight quarters of mid-single-digit or higher growth[8] - The company's organic growth is projected at 7% in 2025[12] - The company's Adjusted EBITDA margin is expected to increase from 13.4% in 2022 to 20.2% in 2025[14] - Cash from Operations is projected to nearly double from 2024 to 2025[19] Market & Strategy - The company operates in a $6.4 billion addressable market[7] - The company has a diversified portfolio in large and growing markets, including Pain Treatments, Surgical Solutions, and Restorative Therapies[8, 6] - The company is focused on margin expansion by leveraging mid-70s gross margin and cost efficiencies[8, 24] - The company aims to increase EBITDA and cash flow to continue reducing leverage[8] Future Outlook - The company projects a net leverage ratio of less than 2.5x by the end of 2025[27] - The company anticipates a free cash flow yield of approximately 60% in 2025[27]